Sign in

Andre Kalil, MD MPH

@drandrekalil.bsky.social
1K followers 81 following 88 posts

Practicing Doc, Transplant ID Director, ID/Critical Care, Clinical Researcher & Trialist. Professor, University of Nebraska Medical Center, Omaha.

PostsRepliesMedia
Reposted by Andre Kalil, MD MPH
Jon Cohen @cohenjon.bsky.social · 17h
Nice to see my boss, Tim Appenzeller, riding the reporter horse again and delivering this history-altering scoop about Rosalind Franklin and her famous photo 51 that helped unravel DNA's structure and function. www.science.org/content/arti...
science.org
How did Rosalind Franklin miss the helix in her iconic DNA image? She didn’t
New analysis refutes James Watson’s claim he was first to recognize significance of famed photograph 51
0117
Reposted by Andre Kalil, MD MPH
Jonathan Ryder, MD @jonathanrydermd.bsky.social · 29/09/2026
Really enjoyed writing this with Ahmad Mourad & @cortes-penfield.bsky.social! See our take on the SNAP trial's results. Well-designed trials supported by other RCTs and observational data warrant elevation of cefazolin to the top spot in MSSA bacteremia treatment #IDSky
1141
Reposted by Andre Kalil, MD MPH
Eli Perencevich @eliowa.bsky.social · 29/09/2026
Presenting symptoms were associated with antibiotic timing, and timely treatment remained associated with lower mortality, even after adjustment for presenting symptoms. jamanetwork.com/journals/jam...
jamanetwork.com
Presenting Symptoms and Antibiotic Timing in Hospitalized Patients With Sepsis
This cohort study evaluates whether any presenting symptoms are associated with timely antibiotic prescription among adults with community-onset presumed bacterial sepsis in Michigan.
033
Reposted by Andre Kalil, MD MPH
Nate Bahr @natebahrid.bsky.social · 16/09/2026
Fungal Awareness Week Day 3. Travel! We're often aware of the fungal infections that happen commonly in our area, but people travel! As physicians, travel histories can help us get to the right diagnosis. If you go into a cave on vacation and have a cough, I'm checking for you for histoplasmosis!
083
Reposted by Andre Kalil, MD MPH
Jonathan Ryder, MD @jonathanrydermd.bsky.social · 16/09/2026
Come join me for this talk discussing PO antibiotic implementation for osteomyelitis, endocarditis, and Staph aureus bacteremia! The data is there, now its just a matter of implementation and adoption! #IDSky
063
Reposted by Andre Kalil, MD MPH
IDWeek @idweek.bsky.social · 15/09/2026
IDWeek is pleased to announce that Andrew T. Pavia, MD, FIDSA, will present this year’s John F. Enders Distinguished Lecture in Medical Virology, “Measles: From Rinderpest to Eradication, and Back.” See @andrewpaviamd.bsky.social present at #IDWeek2026. Register: www.idweek.org/registration
172
Reposted by Andre Kalil, MD MPH
Clinical Microbiology and Infection @cmijournal.bsky.social · 14/09/2026
In honor of #PeerReviewWeek we would like to thank our peer reviewers for their important and insightful contributions to CMI. We deeply value the time, effort and expertise that goes into writing each peer-review.
044
Reposted by Andre Kalil, MD MPH
Clinical Infectious Diseases @cidjournal.bsky.social · 13/09/2026
Antibiotic Timing in Immunocompromised Patients: Effective Therapy as One Piece of a Complex Equation ✅ Just Accepted 🔗 bit.ly/4xS56lw
144
Reposted by Andre Kalil, MD MPH
Jonathan Ryder, MD @jonathanrydermd.bsky.social · 08/09/2026
New Scientific Statement from AHA on Endocarditis!! This is as close as it gets to a new IE guideline POET criteria for PO switch, no more gent for Staph PVE, monotherapy for Staph PVE after valve replacement, ceftriaxone monotherapy for Pen-I Strep, and more!! www.ahajournals.org/doi/10.1161/...
ahajournals.org
Infective Endocarditis: Diagnosis, Antibiotic Therapy, and Management: A Scientific Statement From the American Heart Association | Circulation
Since the publication of the 2015 American Heart Association scientific statement on infective endocarditis, its incidence has increased, its epidemiology has changed, and novel diagnostic and treatme...
094
Reposted by Andre Kalil, MD MPH
Angela Huttner @angelahuttner.bsky.social · 07/09/2026
This one just makes me smile Henning recites Danish poetry 🫶 We learn POET 1 started with a case series, n=12 (every piece of evidence matters!) The two guests are so humble, thoughtful and curious Have a bit of host-envy, @gurujosh.bsky.social & @dremilymcd.bsky.social!! #IDSky #MedSky
194
Reposted by Andre Kalil, MD MPH
Dr. D Boulware, MD MPH @drboulware.bsky.social · 18/09/2025
Mycosis Study Group has released DrFungus app for phones as a reference companion for yeast and mold infections. iPhone apps.apple.com/us/app/dr-fu... Android play.google.com/store/apps/d... App designed by Dr Matt Pullen. @msgerc.bsky.social
apps.apple.com
‎Dr. Fungus
‎The Dr. Fungus app serves as a companion to the official Dr. Fungus website, the Mycoses Study Group Education and Research Consortium resource for fungal disease education. This app provides up-to-d...
1126
Andre Kalil, MD MPH @drandrekalil.bsky.social · 29/08/2026
💥🆕“Hospital Strategies to Improve Sepsis Outcomes” IDSA/ACEP/ASM/PIDS/SCCM/SHEA/SHM/SIDP 👇Free bit.ly/3UnauhT @unmc-id.bsky.social @critcaremed.bsky.social @criticalcarereviews.com #IDSky #MedSky #PCCSky #ICUSky #EMIMCC #Ansky #EMSky #AMSSky #ClinMicro @cidjournal.bsky.social @cmicomms.bsky.social
bit.ly
IDSA/ACEP/ASM/PIDS/SCCM/SHEA/SHM/SIDP Multisociety Position Paper: Hospital Strategies to Improve Sepsis Outcomes
Abstract. Sepsis remains a leading cause of morbidity and mortality in US hospitals despite extensive efforts to improve early recognition and treatment, p
0116
Reposted by Andre Kalil, MD MPH
Madhu Pai, MD, PhD @madhupai.bsky.social · 26/08/2026
Happy to share our new essay in @nature.com Nature Health @gidmk.bsky.social & I offer 7 suggestions to improve observational epidemiology and build trust rdcu.be/fCbVp
04113
Reposted by Andre Kalil, MD MPH
IDSA @idsainfo.bsky.social · 25/08/2026
Our press release: bit.ly/4xqljyq
bit.ly
New multisociety recommendations outline hospital strategies to improve sepsis outcomes
021
Reposted by Andre Kalil, MD MPH
IDSA @idsainfo.bsky.social · 25/08/2026
IDSA and seven other professional societies today released a position paper with evidence-informed recommendations to improve hospital sepsis outcomes. The recommendations cover diagnostics, antimicrobial management, infection prevention and more. Read: bit.ly/4xf7FxO
283
Reposted by Andre Kalil, MD MPH
IDSA @idsainfo.bsky.social · 22/08/2026
Meet the newest voices behind Let’s Talk ID! ID physicians @kcawcutt.bsky.social and @cortes-penfield.bsky.social join the podcast as co-hosts for episodes focused on research published in IDSA journals. (1/2)
2105
Reposted by Andre Kalil, MD MPH
BK. Titanji @boghuma.bsky.social · 21/08/2026
Our new review is out! We examine the JAK/STAT pathway as a therapeutic target in chronic viral infections, including HIV, hepatitis viruses, SARS-CoV-2 & herpesviruses and the balance between reducing harmful inflammation while preserving antiviral immunity. www.frontiersin.org/journals/imm...
frontiersin.org
Frontiers | Targeting the JAK/STAT pathway in chronic viral infections: opportunities and challenges for immunomodulation
The discovery of the Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway as a key regulator of immune function and inflammation ...
14412
Reposted by Andre Kalil, MD MPH
Angela Huttner @angelahuttner.bsky.social · 14/08/2026
Happy to be part of this free online series introducing the use of statistics within clinical trials, conceived and developed by the superstars of ADVANCE-ID #IDSky #MedSky #EpiSky
1135
Reposted by Andre Kalil, MD MPH
Critical Care Reviews @criticalcarereviews.com · 11/08/2026
Clinical metagenomics: a call to action CCR Journal Watch criticalcarereviews.com/latest-evid…
021
Reposted by Andre Kalil, MD MPH
Clinical Infectious Diseases @cidjournal.bsky.social · 09/08/2026
Time to Antibiotics and Mortality in Immunocompromised versus Non-Immunocompromised Patients with Suspected Sepsis 🔁 Repost 🔗 t.co/jPnbwGmsla
185
Reposted by Andre Kalil, MD MPH
Andre Kalil, MD MPH @drandrekalil.bsky.social · 01/08/2026
Thanks for sharing your important story on the candidemia uncertainty challenges.To reduce this uncertainty and improve our patients’ outcomes we developed a specific candidiasis prediction rule for our ICUs at the University of Nebraska Medical Center 👇Free Access link.springer.com/article/10.1...
link.springer.com
Validation and comparison of clinical prediction rules for invasive candidiasis in intensive care unit patients: a matched case-control study - Critical Care
Introduction Due to the increasing prevalence and severity of invasive candidiasis, investigators have developed clinical prediction rules to identify patients who may benefit from antifungal prophyla...
043
Reposted by Andre Kalil, MD MPH
IDSA @idsainfo.bsky.social · 31/07/2026
New #IDSAGuidelines out now! IDSA has released updated evidence-informed guidance on the management of antimicrobial-resistant infections: www.idsociety.org/practice-gui...
1125
Reposted by Andre Kalil, MD MPH
International Immunocompromised Host Society @ichs-global.bsky.social · 29/07/2026
We're grateful for the wonderful feedback and thank you to everyone who made #ICHS2026 a success! "The event was outstanding, and each session was both engaging and insightful." For more information on ICHS Educational opportunities please visit ichs.wildapricot.org/upcoming-and...
022
Reposted by Andre Kalil, MD MPH
Clinical Infectious Diseases @cidjournal.bsky.social · 28/07/2026
Time to Antibiotics and Mortality in Immunocompromised versus Non-Immunocompromised Patients with Suspected Sepsis ✅ Just Accepted 🔗 bit.ly/4vO28g9
153
Reposted by Andre Kalil, MD MPH
Clinical Microbiology and Infection @cmijournal.bsky.social · 27/07/2026
This review explores why MICs can vary between methods, highlights key sources of testing discordance, and discusses clinically important phenomena such as tolerance and heteroresistance that standard MIC testing may miss: www.clinicalmicrobiologyandinfection.org/article/S119...
072
Reposted by Andre Kalil, MD MPH
Clinical Infectious Diseases @cidjournal.bsky.social · 26/07/2026
Skipping to conclusions: Is one negative follow-up blood culture sufficient in Staphylococcus aureus bacteremia? ✅ Just Accepted ✍️ steventong.bsky.social 🔗 bit.ly/4gT9xXR
233
Reposted by Andre Kalil, MD MPH
Jack Iwashyna @iwashyna.bsky.social · 24/07/2026
"One unsolved problem is the profound gap between a better understanding of the pathophysiological background of the [ #septicshock ] resuscitation process and the translation of this knowledge to contemporary research design and clinical practice." link.springer.com/article/10.1...
link.springer.com
Twenty-five years of septic shock hemodynamic resuscitation trials: a conceptual perspective - Critical Care
Background Twenty-five years of septic shock resuscitation trials have progressively transformed the physiological understanding of shock and the way bedside interventions are conceptualized. Early st...
292
Reposted by Andre Kalil, MD MPH
Jonathan Ryder, MD @jonathanrydermd.bsky.social · 23/07/2026
Come join us at the 2026 Nebraska ID Conference! Have an amazing speaker panel, 3 different tracks (stewardship, long term care, and NIDS), and posters from trainees! www.eventbrite.com/e/2026-nebra...
022
Reposted by Andre Kalil, MD MPH
Clinical Microbiology and Infection @cmijournal.bsky.social · 21/07/2026
August 2026 Issue is now online: www.clinicalmicrobiologyandinfection.org/issue/S1198-...
043
Reposted by Andre Kalil, MD MPH
The Lancet Microbe @lancetmicrobe.bsky.social · 15/07/2026
New research article First nationwide full-genome characterisation of human-derived #AndesVirus in Chile: a retrospective genomic epidemiology study www.thelancet.com/journals/lan... #IDSky #ClinMicro #ViroSky #hantavirus #OpenAccess #OA
154
Reposted by Andre Kalil, MD MPH
JAMA Network Open @jamanetworkopen.com · 12/07/2026
In a secondary analysis of the BALANCE randomized clinical trial, 7 days of antibiotics was not associated with increased mortality compared to 14 days among patients with uncomplicated bloodstream infection. ja.ma/4vTJNiz
JAMA Network Open. Original Investigation in Infectious Diseases: 'Procalcitonin to Guide 7 vs 14 Days of Antibiotics in Bloodstream Infections A Secondary Analysis of the BALANCE Trial.' By R. Ramendra et al. Published online June 29, 2026.
143
Reposted by Andre Kalil, MD MPH
Clinical Microbiology and Infection @cmijournal.bsky.social · 13/07/2026
📣 In the July 2026 issue: Association between early SARS-CoV-2 viral rebound and post-COVID conditions among immunocompromised patients: cohort study www.clinicalmicrobiologyandinfection.org/article/S119... #covid #IDSky #MicroSky
032
Reposted by Andre Kalil, MD MPH
CMI Communications @cmicomms.bsky.social · 12/07/2026
🎙️ Just published Communicable E58: Reducing hospital-acquired pneumonia – the HAPPEN trial and how it happened Hosted by Angela Huttner & Josh Davis w/ guests Prof Brett Mitchell, Aline Wolfensberger & Lauren Clack #IDSky #clinmicro Listen on #Communicable: share.transistor.fm/s/825e18f4
075
Reposted by Andre Kalil, MD MPH
Andre Kalil, MD MPH @drandrekalil.bsky.social · 09/07/2026
💥🆕 “Sepsis -Beyond the guidelines” Critical Matters podcast 👇Free Access bit.ly/4vWCmaA @unmc.bsky.social @unmc-id.bsky.social @unmccom.bsky.social @critcaremed.bsky.social @criticalcarereviews.com #IDSky #MedSky #PCCSky #ICUSky #EMIMCC #Ansky #EMSky #AMSSky #meded #Pharmsky #MicroSky #ClinMicro
bit.ly
Sepsis - Beyond the guidelines
In a recent episode, Dr. Sergio Zanotti discussed the 2026 iteration of the Surviving Sepsis Guidelines. In this episode, the discussion continues, focusing on important aspects beyond clinical guidel...
043
Andre Kalil, MD MPH @drandrekalil.bsky.social · 09/07/2026
💥🆕 “Sepsis -Beyond the guidelines” Critical Matters podcast 👇Free Access bit.ly/4vWCmaA @unmc.bsky.social @unmc-id.bsky.social @unmccom.bsky.social @critcaremed.bsky.social @criticalcarereviews.com #IDSky #MedSky #PCCSky #ICUSky #EMIMCC #Ansky #EMSky #AMSSky #meded #Pharmsky #MicroSky #ClinMicro
bit.ly
Sepsis - Beyond the guidelines
In a recent episode, Dr. Sergio Zanotti discussed the 2026 iteration of the Surviving Sepsis Guidelines. In this episode, the discussion continues, focusing on important aspects beyond clinical guidel...
043
Reposted by Andre Kalil, MD MPH
Krutika Kuppalli, MD FIDSA @krutikakuppalli.bsky.social · 09/07/2026
New genomic data suggest the ongoing #Bundibugyo virus outbreak arose from a single zoonotic spillover, with the outbreak lineage likely emerging weeks before detection—underscoring the critical role of genomic surveillance for early outbreak detection and response. virological.org/t/genomic-ep...
virological.org
Genomic epidemiology of the ongoing 2026 Bundibugyo Virus Disease outbreak in the Democratic Republic of the Congo
Genomic epidemiology of the ongoing 2026 Bundibugyo Virus Disease outbreak in the Democratic Republic of the Congo Institut National de Recherche Biomédicale (INRB), Kinshasa – DRC and partners Conte...
15329
Reposted by Andre Kalil, MD MPH
CMI Communications @cmicomms.bsky.social · 09/07/2026
📣New #Communicable drops Mon 13 July! Angela Huttner & Josh Davis are joined by Prof Brett Mitchell, Aline Wolfensberger & Lauren Clack to discuss the HAPPEN trial, a multicentre RCT showing impressive reductions in hospital-acquired #pneumonia, and the studies that led to it.🎙️ #IDSky #clinmicro
085
Reposted by Andre Kalil, MD MPH
JAMA Network Open @jamanetworkopen.com · 08/07/2026
Considering where to publish your next study? JAMA Network Open offers rapid online publication, broad dissemination, extensive media attention, and an Impact Factor of 11.7—all designed to maximize the visibility and impact of your research. Learn more: ja.ma/4ftmoOf
Why Publish in JAMA Network Open? Highlights speed (2 days decision without review, 46 with review), extensive reach (+30,600 media mentions in 2025, broad multimedia coverage), & impact (11.7 Journal Impact Factor, +41M annual views/downloads). JAMA Network Open. logo shown.
033
Reposted by Andre Kalil, MD MPH
Clinical Microbiology and Infection @cmijournal.bsky.social · 08/07/2026
📣 New Supplement publication in CMI The role of whole genome sequencing in antimicrobial susceptibility prediction of bacteria: 2025 update from the #EUCAST Subcommittee @escmid.bsky.social Read here: www.clinicalmicrobiologyandinfection.org/article/S119...
135
Reposted by Andre Kalil, MD MPH
Clinical Microbiology and Infection @cmijournal.bsky.social · 06/07/2026
🌟 The 2025 JCR Impact Factor for CMI has risen to 8.7! We thank our editors, reviewers, authors and readers for their dedication and extraordinary work. Read about how CMI did in 2025 here: clinicalmicrobiologyandinfection.org/article/S119... #IDSky #MicroSky #JIF #JCR2025
064
Reposted by Andre Kalil, MD MPH
BK. Titanji @boghuma.bsky.social · 30/06/2026
Excited to share our latest publication in AIDS! We performed one of the largest multi-ancestry genome-wide association studies of cardiovascular disease in people living with HIV using the Million Veteran Program. We identified a novel genetic locus near NAT8 associated with CVD risk.
2366
Reposted by Andre Kalil, MD MPH
Intensive Care Medicine Journal @intenscaremed.bsky.social · 30/06/2026
#VisualAbstract Appropriate empirical antimicrobial therapy was independently associated with reduced 28-day mortality in critically ill ICU patients with microbiologically confirmed bacterial infections. zurl.co/UBMt4
122
Reposted by Andre Kalil, MD MPH
Critical Care Reviews @criticalcarereviews.com · 29/06/2026
Bayesian Thinking in the Intensive Care Unit: From Statistical Theory to Clinical Practice CCR Journal Watch criticalcarereviews.com/latest-evid…
021
Reposted by Andre Kalil, MD MPH
Critical Care Reviews @criticalcarereviews.com · 29/06/2026
How to use lactate levels to guide septic shock resuscitation: an update CCR Journal Watch criticalcarereviews.com/latest-evid…
053
Reposted by Andre Kalil, MD MPH
Andy Conway Morris @andymoz78.bsky.social · 23/06/2026
Great to see our new paper out in Nature Communications. In it we describe three novel phenotypes in lungs of patients with pneumonia. Pn1 -a non-neutrophil driven lung injury phenotype, Pn2-a balanced immune response with best recovery and Pn3-persistent inflammation driven by immature neutrophils
rdcu.be
Pulmonary inflammation in severe pneumonia is characterised by compartmentalised and mechanistically distinct sub-phenotypes
Nature Communications - Analysis of cell samples from pneumonia patients may indicate specific phenotypes associated with disease. Here the authors use a multi-omics approach to analyse...
2189
Reposted by Andre Kalil, MD MPH
Maricar Malinis @maricarmalinis.bsky.social · 16/06/2026
Join us! @idsainfo.bsky.social immunocompromised host COP’s virtual town hall will be on 6/26— 1 pm EST. Please refer to the email or the myIDSA page for info. @pergamic.bsky.social @emilymeich.bsky.social @arunasubramanian.bsky.social @pearliechong.bsky.social #Andrea_Zimmer @paulksue1.bsky.social
153
Reposted by Andre Kalil, MD MPH
CMI Communications @cmicomms.bsky.social · 05/06/2026
🎙️ A special bonus episode of #Communicable is coming Monday Angela Huttner & Anne-Grete Märtson talk with Daniel Bausch & Martin Grobusch on how #Bundibugyo ebolavirus differs from Zaire & what to expect in the current outbreak #IDSky #Virosky #clinmicro ow.ly/nm5250Z7ViE
086
Reposted by Andre Kalil, MD MPH
Jonathan Ryder, MD @jonathanrydermd.bsky.social · 04/06/2026
Congrats to my colleagues for this interesting analysis. Looking at patients who met DOTS criteria and receive dalbavancin in our hospital, they differ from the DOTS trial Younger, more IDU, more R-sided IE (less SSTI), and more persistent bacteremia. Yet, outcomes similar #IDSky
2208
Reposted by Andre Kalil, MD MPH
JAMA Network Open @jamanetworkopen.com · 04/06/2026
In clinical practice, patients with #Bacteremia receiving dalbavancin were younger and more likely to have substance use or housing instability than those in the DOTS trial, but completed therapy with similar low failure rates. ja.ma/4odctAk
Table 2. Cohort Outcomes Comparisons. DOTS trial (n=100) shows 80% overall clinical success at day 70 & 73% composite efficacy, vs. clinical dalbavancin recipients (n=31) with 65% and 61% respectively.
096
Reposted by Andre Kalil, MD MPH
Clinical Microbiology and Infection @cmijournal.bsky.social · 01/06/2026
In this latest @escmid.bsky.social clinical guideline, a panel of 16 multidisciplinary experts provide recommendations for how to evaluate and manage patients with reported antibiotic allergies. www.clinicalmicrobiologyandinfection.org/article/S119...
096